Investigation launched into Integra LifeSciences over delayed flood impact disclosures.
Johnson Fistel, PLLP is investigating Integra LifeSciences for allegedly misleading investors about the financial impact of a flood at its Cincinnati facility. Initially, Integra downplayed the effects on its 2026 revenue and earnings guidance, but later disclosed significant losses and a delayed operational recovery, causing a 21% drop in shares. The investigation aims to determine if management provided inaccurate information regarding the severity and timeline of the disruption.
Integra LifeSciences Q3FY26 Results: Guidance cut on flood impact
Integra LifeSciences' shares dropped 17% after its preliminary Q3FY26 revenue missed consensus estimates, leading to a cut in its full-year revenue and adjusted EPS guidance. The company attributed the shortfall to a July flooding event at its Cincinnati facility, which is also the subject of a potential securities claims investigation by SueWallSt concerning prior statements made by the CFO. Despite the revenue impact, Integra expects strong cash generation and significant mitigation from insurance recoveries.
Integra LifeSciences cuts 2026 guidance after flooding impact
Integra LifeSciences (NASDAQ: IART) has revised its full-year 2026 financial guidance downwards due to production disruptions caused by July flooding at its Cincinnati manufacturing facility. The company anticipates third-quarter revenue between $410 million and $412 million, and adjusted earnings per diluted share of $0.55 to $0.59. For the full year, revenue is now projected to be $1.634 billion to $1.654 billion, down from the previous range of $1.654 billion to $1.695 billion, with adjusted earnings per share reduced to $2.30 to $2.40 from $2.40 to $2.50.
(IART) Integra LifeSciences Expects Q3 Revenue Range $410M - $412M, vs. FactSet Est of $416.3M
Integra LifeSciences Holdings Corporation (IART) expects its third-quarter revenue to be in the range of $410 million to $412 million, falling short of FactSet's estimated $416.3 million. This announcement comes alongside other news regarding the company's preliminary Q3 results, lowered full-year guidance, and the launch of a $600 million senior secured term loan. The company's shares experienced an 11% pre-bell drop following the news.
A July flood is expected to cut Integra's fourth-quarter revenue by about $15-$20 million
Integra LifeSciences announced preliminary third-quarter results and updated its full-year 2026 guidance, lowering revenue and adjusted EPS expectations due to a July flood at its Cincinnati facility. The flood is anticipated to reduce fourth-quarter revenue by $15 million to $20 million, with full manufacturing operations expected to resume in the second quarter of 2027. Despite the setbacks, Integra expects strong cash generation for the year and anticipates insurance recoveries to mitigate a substantial portion of the financial impact.
Integra LifeSciences lowers revenue and earnings outlook for 2026
Integra LifeSciences (NASDAQ:IART) has lowered its 2026 revenue and adjusted earnings per diluted share guidance due to operational disruptions caused by July flooding in Cincinnati. Despite the reduced outlook, CEO Stuart Essig anticipates strong operating cash flow for both the quarter and the full year, alongside improvements in product availability and commercial execution. The company expects property and business interruption insurance to mitigate much of the financial impact, with full manufacturing operations at the Cincinnati facility projected to resume in Q2 2027.
Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance
Integra LifeSciences (Nasdaq: IART) announced preliminary third-quarter 2026 results and updated its full-year 2026 guidance, citing an impact from a July flooding event at its Cincinnati facility. The company expects third-quarter revenue of $410 million to $412 million and adjusted EPS of $0.55 to $0.59, and has lowered its full-year revenue outlook to $1.634 billion to $1.654 billion and adjusted EPS to $2.30 to $2.40. Despite the reduction, Integra anticipates strong operating cash flow of approximately $190 million to $200 million for the full year and expects insurance recoveries to mitigate much of the financial impact from the Cincinnati facility disruption.
Integra LifeSciences Announces 100th Patient Enrolled in AERA® Pediatric Registry
Integra LifeSciences announced the enrollment of its 100th patient in the AERA® Pediatric Registry, a significant step toward its goal of 300 patients. This registry evaluates the Acclarent AERA Eustachian Tube Balloon Dilation System's effectiveness in pediatric patients aged eight and older with obstructive Eustachian tube dysfunction. The AERA system received FDA clearance for its pediatric indication in December 2023, making it the first and only such system for this age group.
A registry tracking an ear treatment for children has enrolled 100 of its planned 300 patients.
Integra LifeSciences announced that its AERA Pediatric Registry has enrolled its 100th patient, reaching one-third of its target of 300 patients. This registry evaluates the AERA Eustachian Tube Balloon Dilation System for children aged eight and older with obstructive Eustachian tube dysfunction. The system received FDA clearance for pediatric use in December 2023.
Integra LifeSciences Marks 20 Years of CUSA® Technology with Liver Surgery Education at ACS Clinical Congress 2026
Integra LifeSciences is celebrating 20 years of its CUSA® technology at the American College of Surgeons (ACS) Clinical Congress 2026. The company will host surgeon-led educational programming focusing on liver surgery, featuring presentations by internationally recognized experts. This initiative aims to advance education and collaboration in liver surgery, a critical field given the high global incidence of liver cancer.
More than 800,000 people are diagnosed with liver cancer yearly. Surgeons will discuss complex liver procedures.
Integra LifeSciences will showcase its CUSA and MicroFrance technologies at the ACS Clinical Congress 2026, celebrating 20 years of CUSA technology. The event will feature educational programming and discussions led by liver surgeons, focusing on complex liver procedures. This initiative highlights the ongoing importance of collaboration and education in treating conditions like liver cancer, which affects over 800,000 people annually.
Integra LifeSciences (IART) Stock May Be 48% Undervalued On Cash Flow
Integra LifeSciences (IART) stock is currently trading at US$16.02, but analysis suggests it may be significantly undervalued based on its future cash flow generation. Despite a 77.3% decline over the past five years, analysts forecast a recovery in free cash flow, which, when discounted, indicates an intrinsic value substantially higher than the current share price. This discrepancy suggests the market isn't fully pricing in the anticipated turnaround in the company's cash flow performance.
Integra LifeSciences to Present at the 2026 Wells Fargo Healthcare Conference and the 2026 Morgan Stanley Healthcare Conference
Integra LifeSciences Holdings Corporation announced that its executives, Lea Knight and Michael McBreen, will present at the 2026 Wells Fargo Healthcare Conference on September 9, 2026. Additionally, Stuart Essig will present at the 2026 Morgan Stanley Healthcare Conference on September 15, 2026. Live webcasts of these presentations will be available on the company's investor relations website.
Integra LifeSciences: Strong Q2 2026 Results Support Recovery Thesis (NASDAQ:IART)
Integra LifeSciences (IART) reported strong Q2 2026 results, beating earnings estimates and expanding margins, reinforcing its recovery thesis. The company's specialty surgery segment drove revenue growth, and while tissue reconstruction saw declines, the successful PriMatrix relaunch and upcoming SurgiMend reintroduction are expected to offset this. Management aims to reduce leverage to 2.5–3.5x by year-end 2026, and IART trades at a significant EV/EBITDA discount, presenting potential for earnings upside through product relaunches.
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Integra LifeSciences (IART) Investors of Pending Securities Fraud Class Action, Encourages Investors with Substantial Losses to Contact Firm's Attorneys
Hagens Berman is reminding Integra LifeSciences (IART) investors of a pending securities fraud class action lawsuit. The litigation focuses on Integra's alleged false and misleading statements regarding FDA violations at its Boston Facility, which led to a product recall and production halt. Investors who suffered substantial losses are encouraged to contact Hagens Berman to discuss their legal rights.
Is IART Still Attractive as Its Low Valuation Meets Execution Risks?
Integra LifeSciences Holdings Corp. (IART) trades at a significant valuation discount compared to its industry and market benchmarks, driven by recent margin gains and improved operating execution. However, the company faces challenges including modest revenue growth, elevated leverage, and unresolved regulatory remediation with the FDA. Despite these risks, Integra's operational improvements and cost savings offer support for its earnings outlook, making execution crucial for its investment appeal.
Integra LifeSciences /US Number of Employees 2026 | Employee Count & Headcount Data
Integra LifeSciences Holdings Corp. (IART) had approximately 4,344 employees worldwide as of March 2026, representing a 0.6% decline from 2023. The company is actively hiring, with 272 active job postings in 2026, though this is a significant decline from previous years. The workforce is concentrated in North America, and overall employee sentiment is reported as negative and declining.
Assenagon Asset Management S.A. Reduces Position in Integra LifeSciences Holdings Corporation $IART
Assenagon Asset Management S.A. significantly reduced its stake in Integra LifeSciences Holdings Corporation by 66.3% in the second quarter of 2026, selling over 276,000 shares. Despite this, other institutional investors like Rubric Capital Management LP and Paradigm Capital Management Inc. NY increased their holdings. The stock opened up 4.9% at $18.24 following a beat on quarterly EPS and revenue, with analysts maintaining a cautious "Reduce" average rating but an Argus upgrade to "Buy."
Paradigm Capital discloses 4.42% Integra LifeSciences (IART) stake with sole voting control
Paradigm Capital Management, Inc. has reported an amended stake in Integra LifeSciences Holdings Corp (IART), disclosing beneficial ownership of 3,439,098 shares, which represents 4.42% of the outstanding common stock. The New York S corporation maintains sole voting and dispositive power over all these shares. This filing characterizes their holding as ownership of 5 percent or less of the class, aligning with regulatory reporting thresholds.
Quantinno Capital Management LP Reduces Holdings in Integra LifeSciences Holdings Corporation $IART
Quantinno Capital Management LP significantly reduced its stake in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 45.4% in the first quarter of 2026, selling 382,663 shares. Despite this reduction, other institutional investors like Paradigm Capital, Sei Investments, and Walleye Capital increased their holdings, maintaining high institutional ownership at 84.78%. Integra LifeSciences exceeded Q1 2026 earnings expectations with $0.56 EPS and $418.76 million in revenue, but analysts maintain a cautious "Reduce" rating with an average price target of $18.86.
5 Must-Read Analyst Questions From Integra LifeSciences’s Q2 Earnings Call
Integra LifeSciences reported Q2 results with flat revenue due to reimbursement pressures and challenging year-over-year comparisons, though adjusted EPS outperformed expectations. Analysts focused on the company's full-year guidance, CEO's return, demand for Integra Skin, and the relaunch of SurgiMend. Upcoming quarters will see monitoring of SurgiMend's relaunch, cost savings, and supply chain stability.
Glenmede Trust Co. NA Raises Stock Holdings in Integra LifeSciences Holdings Corporation $IART
Glenmede Trust Co. NA increased its stake in Integra LifeSciences Holdings Corporation by 27.4% in the first quarter, bringing its total holdings to 984,686 shares valued at $9.3 million. Several other institutional investors also increased their positions, resulting in institutional investors owning 84.78% of IART's outstanding shares. Despite the company beating quarterly earnings expectations, analysts currently maintain an average "Reduce" rating for the stock.
UBS initiates Integra LifeSciences stock with neutral rating
UBS has initiated coverage on Integra LifeSciences Holdings Corporation (NASDAQ:IART) with a Neutral rating and a $19.00 price target, noting the company's sound fundamental building blocks despite recent challenges. The stock has seen a significant 79.5% surge in the past six months and is currently trading near its 52-week high. Analysts predict profitability this year, and the company's debt is considered manageable.
Integra LifeSciences Holdings Corporation $IART Stock Position Trimmed by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP reduced its stake in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 10.1% in the first quarter, although institutional investors still collectively own 84.78% of the company's stock. Integra LifeSciences recently reported Q2 EPS of $0.56, exceeding analyst estimates, and provided Q3 and full-year 2026 guidance. Analyst sentiment remains cautious, with a consensus "Reduce" rating and an average price target of $18.86.
integra lifesciences holdings corp Profit Warnings
This page provides information on Integra Lifesciences Holdings Corp's profit warnings and related financial news. It lists a specific profit warning for FY26 with a revised revenue range. The page also features a compilation of recent news articles concerning Integra LifeSciences, detailing earnings, leadership changes, and FDA clearances.
Integra LifeSciences (IART) 10K Form and Latest SEC Filings 2026
This article details Integra LifeSciences' (IART) SEC filings history, emphasizing that these documents are crucial for investors as a primary source of verified financial data. It highlights the company has submitted over 437 documents since 2017, with the most recent being a Form SCHEDULE 13G on July 31, 2026. The article also explains the importance and differences between common SEC filing types like 10-K, 10-Q, 8-K, and Form 4, providing a comprehensive overview for investors tracking IART.
Vanguard Portfolio Management (IART) discloses 3.9M-share position in Integra
Vanguard Portfolio Management has disclosed a beneficial ownership of 3,912,816 shares, representing 5.02% of Integra LifeSciences Holdings Corp (IART) common stock, as of June 30, 2026. This Schedule 13G filing indicates Vanguard has sole voting power over 169,723 shares and sole dispositive power over all 3,912,816 shares, with no shared voting or dispositive power. The filing also clarifies that no other single entity has an interest in more than 5% of these reported securities.
Zacks.com featured highlights include Bassett Furniture, Aveanna Healthcare and Integra LifeSciences
Zacks.com has identified Bassett Furniture Industries (BSET), Aveanna Healthcare Holdings (AVAH), and Integra LifeSciences Holdings (IART) as stocks with breakout potential ahead of August. The article emphasizes identifying stocks within defined trading ranges and highlights the importance of support and resistance levels to spot genuine breakout opportunities. These three companies are recommended based on their Zacks Rank and expected earnings growth rates.
Integra Lifesciences Holdings Corp (IART) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for Integra Lifesciences Holdings Corp (IART), highlighting its current valuation score of 8.05, which ranks 83rd in the Healthcare Equipment & Supplies industry. It details the company's current P/E ratio at -2.58, noting significant deviations from recent highs and lows. The analysis also indicates that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
IART|Integra Lifesciences Holdings Corp|Price:17.842|Chg%:+1.192
This article provides a detailed profile of Integra LifeSciences Holdings Corporation (IART), a global medical technology company. It outlines the company's two main segments, Codman Specialty Surgical (CSS) and Tissue Technologies (TT), and their respective product portfolios. The report also includes company information, key executive details with their shareholdings, and FAQs regarding top shareholders, institutional holdings, and primary revenue sources.
Zacks.com featured highlights include Bassett Furniture, Aveanna Healthcare and Integra LifeSciences
This article identifies Bassett Furniture Industries (BSET), Aveanna Healthcare Holdings (AVAH), and Integra LifeSciences Holdings (IART) as potential breakout stocks for August. It outlines a strategy for spotting such opportunities by analyzing support and resistance levels. The article emphasizes that while correctly identifying these stocks can lead to significant returns, investors should be aware of the risks involved in timing breakout candidates.
Integra Lifesciences Q3 Results: Sales guidance beats estimates
Integra Lifesciences projects Q3 adjusted EPS between $0.53-$0.61 and sales of $410-$425 million, with the sales guidance exceeding analyst estimates. While profit expectations align with consensus, the higher sales forecast indicates potential revenue upside. This guidance highlights the company's confidence in maintaining demand and managing costs effectively amidst varying market dynamics.
Integra Lifesciences Latest Results: Sales guidance lowered to $1.654B-$1.695B
Integra Lifesciences has lowered its sales guidance for FY2026 to a range of $1.654 billion to $1.695 billion, which is below the analyst consensus estimate of $1.676 billion. Despite this downward revision in revenue, the company affirmed its adjusted earnings per share (EPS) guidance at $2.40 to $2.50, matching analyst estimates. This indicates a focus on maintaining profitability through cost efficiencies or margin expansion even with anticipated weaker top-line growth.
Integra: Q2 Earnings Snapshot
This article provides a second-quarter earnings snapshot for Integra.
Integra LifeSciences Reports Second Quarter 2026 Results, Updates Full-Year Revenue Guidance and Reaffirms EPS Outlook
Integra LifeSciences announced its Q2 2026 financial results, reporting revenues of $418.8 million and a significant improvement in GAAP net income from a loss to $4.5 million. The company updated its full-year revenue guidance due to foreign exchange impacts but reaffirmed its organic growth and adjusted EPS outlook. Integra also highlighted operational progress, including the start of production at its Braintree facility for the SurgiMend relaunch.
Integra starts production for planned fourth-quarter SurgiMend relaunch
Integra LifeSciences (Nasdaq: IART) reported Q2 2026 revenue of $418.8 million, a 0.8% increase year-over-year, with GAAP EPS at $0.06 and adjusted EPS at $0.56. The company reaffirmed its full-year 2026 organic revenue growth and adjusted EPS guidance, while slightly lowering reported revenue guidance due to foreign exchange impacts. Crucially, Integra initiated production at its Braintree facility, staying on track for a planned fourth-quarter relaunch of its SurgiMend product.
Integra LifeSciences earnings up next: Can turnaround hold?
Integra LifeSciences is set to report second-quarter earnings, with investors looking for sustained operational recovery following manufacturing issues. Analysts project $0.48 EPS and $417.6 million in revenue, but maintain a neutral rating due to past guidance cuts and questions about consistent results. The company's ability to maintain or raise guidance and expand its gross margin will be key indicators of whether its recent performance signals a true turnaround.
Integra Lifesciences Holdings Corp (IART) Dividends & Stock Splits: Historical Payouts and Event Timeline
The article provides an overview of Integra Lifesciences Holdings Corp's (IART) dividend history and stock splits. It states that the company has distributed a total of $0.00 in dividends over the past five years, indicating no recent dividend payouts. Key information like market cap, P/E ratio, and current stock price is also displayed.
Integra Lifesciences Holdings Corp
This article provides a detailed revenue breakdown for Integra Lifesciences Holdings Corp (IART) by business segments and geographical regions. It shows Neurosurgery as the largest revenue contributor among business segments, and the United States as the dominant region for its revenue. The financial data is updated as of April 6, covering fiscal years up to 2025.
IART|Integra Lifesciences Holdings Corp|Price:19.530|Chg%:-0.260
This article provides a comprehensive stock analysis of Integra Lifesciences Holdings Corp (IART) based on TradingKey's stock score system. It highlights the company's stable fundamentals, high growth potential, and fair valuation within the Healthcare Equipment & Supplies industry. The analysis also notes high institutional ownership, a "Hold" analyst rating, and an expectation for the stock price to trend upward in the medium term, despite recent average market performance.
IART|Integra Lifesciences Holdings Corp|Price:19.790|Chg%:+1.230
This article provides a detailed financial overview of Integra Lifesciences Holdings Corp (IART), including its stock price, market capitalization, and upcoming earnings date. It presents a comprehensive data dashboard with quarterly and annual financial statements such as income statement, balance sheet, and cash flow statement. Key financial indicators like EPS, revenue, net profit, and various margins are displayed, alongside answers to frequently asked questions regarding the company's financial performance.
TradingKey
This article provides a detailed quarterly and annual balance sheet analysis for Integra Lifesciences Holdings Corp (IART) from FY2012Q1 to FY2026Q1, highlighting various asset, liability, and equity metrics. It allows users to evaluate the company's financial health, fundamentals, and key ratios. The report includes year-over-year percentage changes and absolute values for items like cash, receivables, inventory, debt, and shareholder equity.
Integra Lifesciences Holdings Corp (IART) Cash Flow Statement
This article presents the quarterly and annual cash flow statements for Integra Lifesciences Holdings Corp (IART), allowing users to assess the company's financial health. It includes detailed breakdowns of operating, investing, and financing cash flows, along with frequently asked questions defining these terms and providing IART's recent figures.
Integra LifeSciences Holdings Corporation (IART) Stock Price, News, Quote & History
This article provides a comprehensive overview of Integra LifeSciences Holdings Corporation (IART), including its current stock price, financial statistics, and company profile. It details the company's performance, product offerings in medical devices, and recent analyst ratings. The information aims to give investors a snapshot of IART's financial health and market position.
Integra Lifesciences Holdings Corp (IART) Financial Health: Profitability & Balance Sheet Analysis
This article analyzes the financial health of Integra Lifesciences Holdings Corp (IART), noting its weak financial status but high operating efficiency. The company's financial score is 6.96, ranking 121 out of 200 in its industry. Integra Lifesciences recently reported a 2.42% year-over-year revenue increase and an 81.75% increase in net profit.
Kaskela Law Firm Announces Investigation of Integra LifeSciences
Kaskela Law Firm has launched an investigation into Integra LifeSciences Holdings Corp. (NASDAQ: IART) following the filing of a securities fraud complaint. The complaint alleges that Integra made false and misleading statements regarding systemic cGMP violations and product quality issues from March 2019 to May 2023, leading to a significant stock price drop after these deficiencies were disclosed. The firm is encouraging long-term shareholders with losses who purchased shares before April 26, 2023, to contact them to discuss their legal rights.
Integra Lifesciences Holdings Corp|Price:19.790|Chg%:+1.230
Integra Lifesciences Holdings Corp (IART) saw a price increase of 6.63% to $19.790, with its fundamentals noted as stable and growth potential high, despite technical indicators not fully supporting the current trend. The stock is currently trading sideways, suitable for range-bound swing trading, and analysts rate it as Hold with a target price of $18.833. The company is a global medical technology firm operating in two main segments: Codman Specialty Surgical and Tissue Technologies.
Integra LifeSciences to announce Q2 2026 results on July 29
Integra LifeSciences Holdings Corporation announced it will release its second-quarter 2026 financial results on July 29, 2026, before the market opens. Following the release, the management team will host a conference call at 8:30 a.m. ET to discuss the results and outlook, with a live webcast available on the company's investor website. This announcement comes after BMO Capital initiated coverage on Integra Lifesciences with a Market Perform rating and a $19 price target.
Integra LifeSciences to Release Results Before Market Open July 29
Integra LifeSciences (NASDAQ: IART) announced that it will release its second-quarter 2026 financial results on Wednesday, July 29, 2026, before the market opens. Management will host an earnings conference call at 8:30 a.m. ET, which will be accessible via live webcast and replay on the company's investor relations website. Following this announcement, the stock saw a positive market reaction, gaining 5.38% and adding approximately $79 million to its valuation.
Integra LifeSciences to Host Second Quarter 2026 Financial Results Conference Call on July 29, 2026
Integra LifeSciences Holdings Corporation will release its second quarter 2026 financial results on Wednesday, July 29, 2026, before the market opens. Following the release, the management team will host a conference call at 8:30 a.m. ET, with a live webcast available on the company's investor relations website. A webcast replay will also be accessible on the website after the call.
